She underwent excisional biopsy of a 2.1-mm thick melanoma from her right ankle in the spring of [**2105**].
Dr. [**Last Name (STitle) **] performed a right superficial inguinal femoral lymphadenectomy with right sartorius rotation flap on [**2106-7-16**] with pathology showing microscopic melanoma in [**12-22**] residual lymph nodes.
She underwent skin biopsy of a left posterior thigh lesion in [**2107-1-12**] revealing a 0.62-mm thick superficial spreading melanoma, [**Doctor Last Name 10834**] level IV without ulceration for which she underwent re-excision on [**2107-2-2**] without residual melanoma noted.
She developed worsening right lower extremity edema in late [**2109-10-12**] with abdominal pelvic CT revealing retroperitoneal and pelvic lymphadenopathy.
She underwent CT-guided biopsy of a pelvic node revealing metastatic melanoma.
She now is admitted to begin cycle 1 week on high-dose IL-2 therapy.
p.r.n., Percocet 1-2 tablets every 4 hours p.r.n.
LABS ON ADMISSION:  WBC 11.2, hemoglobin 10.9, hematocrit 31.6, platelet count 496,000, BUN 17, creatinine 0.8, sodium 137, potassium 3.9, chloride 99, CO2 30, glucose 86 INR 1.1, ALT 10, AST 16, albumin 3.8.
Her admission weight was 68 kg and she received interleukin II 600,000 international units per kilo equaling 40.8 million units IV every 8 hours times 14 potential doses.
Chest x-ray was consistent with that and she was treated with Lasix with good urine output.
She developed transaminitis with a peak ALT of 87 and peak AST of 99, both improved at the time of discharge.
She developed hyperbilirubinemia with peak bilirubin of 4 improved to 1 at the time of discharge.
She developed thrombocytopenia with a platelet count low of 11,000, improved to 111,000 at the time of discharge.
Week 2 of therapy will not be administered at this time but we will plan to follow up with CT scans at week 7 to assess disease response to determine whether treatment again would be warranted.
